Sign in

CIK 0001680581

  • Non-accelerated filer
  • Smaller reporting company

Fulcrum Therapeutics, Inc.

Sign in to watch
Ticker
FULC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
474839948
Phone
+1 617-651-8851
Business address
26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2019-07-22 Third Rock Ventures III, L.P. 10% owner Conversion · Series A Preferred Stock −39,166,667 0
2019-07-22 Third Rock Ventures III, L.P. 10% owner Conversion · Series A Preferred Stock −0 0
2019-07-18 Wallace Owen B. Chief Scientific Officer Grant or award · Stock Option (right to buy) +44,493 44,493
2019-07-18 Collins James J. Director Grant or award · Stock Option (right to buy) +5,714 5,714
2019-07-18 GERAGHTY JAMES A Director Grant or award · Stock Option (right to buy) +9,285 9,285
2019-07-18 Ezekowitz Alan Director Grant or award · Stock Option (right to buy) +5,714 5,714
2019-07-18 Haviland Kate Director Grant or award · Stock Option (right to buy) +9,285 9,285
2019-07-18 Gould Robert J Grant or award · Stock Option (right to buy) +107,142 107,142
2019-07-18 Cadavid Diego Grant or award · Stock Option (right to buy) +12,784 12,784
2019-07-18 Stuart Bryan Chief Operating Officer Grant or award · Stock Option (right to buy) +28,571 28,571
2019-07-18 Thomson Peter G. Grant or award · Stock Option (right to buy) +7,078 7,078

Page 15 of 15 · 291 trades